Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Aug;61(8):722-8.
doi: 10.1136/thx.2005.045161.

Asthma exacerbations . 1: epidemiology

Affiliations

Asthma exacerbations . 1: epidemiology

N W Johnston et al. Thorax. 2006 Aug.

Abstract

Asthma exacerbations may be triggered by a number of atmospheric and domiciliary environmental factors as well as by those encountered in schools and workplaces. The majority of exacerbations, particularly in children, coincide with respiratory viral infections, most commonly rhinovirus. As most respiratory viruses and many aeroallergens appear in seasonal patterns, asthma exacerbations, particularly those requiring emergency treatment, show analogous seasonal cycles which differ in form in children and adults. While similar in form between the sexes, they differ in amplitude, with boys having higher risks of exacerbation in childhood and women in adult life. Simultaneous exposure of asthmatics with respiratory viral infections to allergens or air pollutants may significantly increase the risks of exacerbation. Access to and compliance with inhaled corticosteroid treatment is an important predictor of the likelihood of asthma exacerbations occurring, including those that occur during respiratory viral infections. Epidemiologically, the degree of asthma control achieved by asthmatics is an important predictor of the likelihood of disease exacerbation including respiratory failure, death, and health service consumption.

PubMed Disclaimer

Conflict of interest statement

Competing interests: MS has received research funds, consulting fees, and speaking fees from pharmaceutical companies with asthma products including Altana, AstraZeneca, Centocor, GlaxoSmithKline, Merck Frosst Canada, Merck‐Sharpe Dohme, and Schering. NJ has received research funds and/or consulting and/or speaking fees from the following pharmaceutical companies with asthma products: GlaxoSmithKline Canada, AstraZeneca Canada, Merck Frosst Canada, and Altana Pharma.

Similar articles

Cited by

References

    1. Lane S, Molina J, Plusa T. An international observational prospective study to determine the cost of asthma exacerbations (COAX). Respir Med 2006100434–450. - PubMed
    1. Skrepnek G H, Skrepnek S V. Epidemiology, clinical and economic burden, and natural history of chronic obstructive pulmonary disease and asthma. Am J Manag Care 200410(5 Suppl)S129–S138. - PubMed
    1. Andersson F, Borg S, Stahl E. The impact of exacerbations on the asthmatic patient's preference scores. J Asthma 20035615–623. - PubMed
    1. Pauwels R A, Lofdahl C G, Postma D S.et al Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 19973371405–1411. - PubMed
    1. Johnston N W, Sears M R. Seasonal patterns of asthma exacerbations. In: Johnston SL, O'Byrne P, eds. Exacerbations of asthma. London: Parthenon Publishing Group, 2006. (in press)

Publication types

Substances